Tags

Type your tag names separated by a space and hit enter

Effects of acute oral Delta9-tetrahydrocannabinol and standardized cannabis extract on the auditory P300 event-related potential in healthy volunteers.
Eur Neuropsychopharmacol 2008; 18(8):569-77EN

Abstract

Reduced amplitudes of auditory evoked P300 are a robust finding in schizophrenic patients, indicating deficient attentional resource allocation and active working memory. Delta9-Tetrahydrocannabinol (Delta9-THC), the main active constituent of Cannabis sativa, has been known to acutely impair cognitive abilities in several domains, particularly in memory and attention. Given the psychotic-like effects of Delta9-THC, a cannabinoid hypothesis of schizophrenia has been proposed. This prospective, double-blind, placebo-controlled cross-over study investigated the acute effects of cannabinoids on P300 amplitude in 20 healthy volunteers (age 28.2+/-3.1 years, 10 male) by comparing Delta9-THC and standardized cannabis extract containing Delta9-THC and cannabidiol (CBD). P300 waves were recorded during a choice reaction task. As expected, Delta9-THC revealed a significant reduction of P300 amplitude at midline frontal, central, and parietal electrodes. CBD has been known to abolish many of the psychotropic effects of Delta9-THC, but, unexpectedly, failed to demonstrate a reversal of Delta9-THC-induced P300 reduction. Moreover, there were no correlations between cannabinoid plasma concentrations and P300 parameters. These data suggest that Delta(9)-THC may lead to acute impairment of attentional functioning and working memory. It can be speculated whether the lack of effect of CBD may be due to an insufficient dose used or to an involvement of neurotransmitter systems in P300 generation which are not influenced by CBD.

Authors+Show Affiliations

Department of Psychiatry, Ruhr-University Bochum, Bochum, Germany. patrik.roser@wkp-lwl.orgNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Controlled Clinical Trial
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

18544469

Citation

Roser, Patrik, et al. "Effects of Acute Oral Delta9-tetrahydrocannabinol and Standardized Cannabis Extract On the Auditory P300 Event-related Potential in Healthy Volunteers." European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology, vol. 18, no. 8, 2008, pp. 569-77.
Roser P, Juckel G, Rentzsch J, et al. Effects of acute oral Delta9-tetrahydrocannabinol and standardized cannabis extract on the auditory P300 event-related potential in healthy volunteers. Eur Neuropsychopharmacol. 2008;18(8):569-77.
Roser, P., Juckel, G., Rentzsch, J., Nadulski, T., Gallinat, J., & Stadelmann, A. M. (2008). Effects of acute oral Delta9-tetrahydrocannabinol and standardized cannabis extract on the auditory P300 event-related potential in healthy volunteers. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology, 18(8), pp. 569-77. doi:10.1016/j.euroneuro.2008.04.008.
Roser P, et al. Effects of Acute Oral Delta9-tetrahydrocannabinol and Standardized Cannabis Extract On the Auditory P300 Event-related Potential in Healthy Volunteers. Eur Neuropsychopharmacol. 2008;18(8):569-77. PubMed PMID: 18544469.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effects of acute oral Delta9-tetrahydrocannabinol and standardized cannabis extract on the auditory P300 event-related potential in healthy volunteers. AU - Roser,Patrik, AU - Juckel,Georg, AU - Rentzsch,Johannes, AU - Nadulski,Thomas, AU - Gallinat,Jürgen, AU - Stadelmann,Andreas M, Y1 - 2008/06/10/ PY - 2008/01/13/received PY - 2008/04/14/revised PY - 2008/04/17/accepted PY - 2008/6/12/pubmed PY - 2008/11/6/medline PY - 2008/6/12/entrez SP - 569 EP - 77 JF - European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology JO - Eur Neuropsychopharmacol VL - 18 IS - 8 N2 - Reduced amplitudes of auditory evoked P300 are a robust finding in schizophrenic patients, indicating deficient attentional resource allocation and active working memory. Delta9-Tetrahydrocannabinol (Delta9-THC), the main active constituent of Cannabis sativa, has been known to acutely impair cognitive abilities in several domains, particularly in memory and attention. Given the psychotic-like effects of Delta9-THC, a cannabinoid hypothesis of schizophrenia has been proposed. This prospective, double-blind, placebo-controlled cross-over study investigated the acute effects of cannabinoids on P300 amplitude in 20 healthy volunteers (age 28.2+/-3.1 years, 10 male) by comparing Delta9-THC and standardized cannabis extract containing Delta9-THC and cannabidiol (CBD). P300 waves were recorded during a choice reaction task. As expected, Delta9-THC revealed a significant reduction of P300 amplitude at midline frontal, central, and parietal electrodes. CBD has been known to abolish many of the psychotropic effects of Delta9-THC, but, unexpectedly, failed to demonstrate a reversal of Delta9-THC-induced P300 reduction. Moreover, there were no correlations between cannabinoid plasma concentrations and P300 parameters. These data suggest that Delta(9)-THC may lead to acute impairment of attentional functioning and working memory. It can be speculated whether the lack of effect of CBD may be due to an insufficient dose used or to an involvement of neurotransmitter systems in P300 generation which are not influenced by CBD. SN - 0924-977X UR - https://www.unboundmedicine.com/medline/citation/18544469/Effects_of_acute_oral_Delta9_tetrahydrocannabinol_and_standardized_cannabis_extract_on_the_auditory_P300_event_related_potential_in_healthy_volunteers_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0924-977X(08)00106-5 DB - PRIME DP - Unbound Medicine ER -